Infections of the Nervous System and Senses
After reading this chapter, the student will be able to:
• Describe how microorganisms can gain access to the nervous system
• Describe the symptoms of meningitis; discuss the different causes and the different treatment approaches for each type of the illness
• Discuss the different forms of bacterial meningitis; include the cause, symptoms, and treatments
• Describe the four different types of tetanus and the causes, prevention, and treatment
• Discuss botulism and the different types of toxins produced by the different strains
• Explain the causes, symptoms, and treatment of leprosy
• Describe the causes, symptoms, and treatment of conjunctivitis
• Describe the causes, symptoms, prevention, and treatments of poliomyelitis, rabies, and arboviral encephalitis
• Describe the typical fungal infections of the human nervous system
• Differentiate between African and American trypanosomiasis
• Describe prions and the human diseases associated with them
Introduction
The nervous system is divided into two components: the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS consists of the brain and spinal cord, and the PNS consists of 12 pairs of cranial nerves, 31 pairs of spinal nerves, ganglia, and associated sensory receptors (Figure 13.1). The brain and the spinal cord are covered by three protective membranes, collectively called meninges (Figure 13.2). The outermost membrane is the dura mater, the middle layer is the arachnoid, and the innermost membrane is the pia mater. The space between the pia mater and the arachnoid, referred to as the subarachnoid space, contains cerebrospinal fluid (CSF), which circulates through the brain ventricles, the central canal of the spinal cord, and the subarachnoid space. The CSF has a low level of complement proteins, circulating antibodies, and some phagocytotic cells; if bacteria get access to the CSF they can multiply with little immune reaction by the body.
During a CNS infection specific changes occur within the CSF. The response in the CSF to a viral infection is generally reflected by an increase in lymphocytes, monocytes, and a slight increase in proteins, and the CSF remains clear. This condition is called aseptic meningitis. In the case of a bacterial infection a rapid increase in granulocytes and proteins occurs and the CSF becomes visibly turbid. This condition is called septic meningitis (Table 13.1).
TABLE 13.1
Cerebrospinal Fluid (CSF) Changes During CSF Infections
Cause | Cells/ml | Protein (mg/dl) | White Blood Cells | |
Normal | 0–5 | 15–45 | ||
Aseptic meningitis or meningoencephalitis | Viruses, tuberculosis, leptospira, fungi, brain abscess | 100–1000 | 50–100 | Elevated lymphocytes and monocytes |
Septic meningitis | Bacteria, amoebae, brain abscess | 200–20,000 | High (>100) | Elevated granulocytes |
The CNS is remarkably resistant to infection, largely because of a barrier between the blood circulation and the nervous tissue, referred to as the blood–brain barrier. The capillaries of the blood–brain barrier permit only selected substances to pass from the blood into the brain, with all others being restricted. In essence, only lipid-soluble substances can cross the barrier; the exception is glucose and certain amino acids, none of which are lipid soluble, but that have specific carrier mechanisms transporting them across the barrier. Unless they are lipid soluble, drugs cannot cross the blood–brain barrier. For example, chloramphenicol, a lipid-soluble antibiotic (see Chapter 22, Antimicrobial Drugs), can readily enter the brain whereas penicillin, only slightly lipid soluble, is effective only if taken in large doses.
Another structure that can be affected by microorganisms or their toxins is the neuromuscular junction. The neuromuscular junction (Figure 13.3) is the connection between the synaptic end bulb (axon terminal) of a motor neuron, located in the spinal cord, and a muscle fiber. This junction is essential for muscle contraction. The two cells do not touch each other but are separated by a small space called the synaptic cleft. The electrical message from the motor neuron is translated into a chemical message via the neurotransmitter (acetylcholine) located in the presynaptic terminal. Once the neurotransmitter is released into the synaptic cleft it diffuses to the receptors on the muscle fiber and generates another electrical event that leads to muscle contraction. Any interference with this delicate structure will lead to problems with muscle contraction.
Bacterial Infections
Bacterial Meningitis
Bacterial meningitis is less common than viral meningitis but is more severe in nature, because of the production of toxins by the bacteria. The mortality rate for bacterial meningitis varies with the causative agent, and vaccination is available for some. Early diagnosis and treatment of bacterial meningitis are essential to prevent permanent neurological damage. Antibacterial drugs used to treat bacterial meningitis include penicillin G, ampicillin or amoxicillin, chloramphenicol, cefotaxime, vancomycin, and ceftriaxone (see Chapter 22, Antimicrobial Drugs).
Meningococcal Meningitis
Outbreaks of meningococcal meningitis occur globally. It is endemic in temperate climates, with sporadic cases or small clusters of cases exhibiting seasonal increases in winter and spring. In the United States sporadic outbreaks occur among college students who live in dormitories. Epidemics of meningococcal meningitis have occurred in Africa in periodic waves. In 2002 outbreaks occurred in the Great Lakes region of Central Africa in villages and refugee camps. More than 2200 cases were reported, including 200 deaths (Table 13.2). More recently, during 2007, 54,676 suspected cases of meningitis and 4062 deaths were reported from the “meningitis belt” region in Africa. This region covers 21 sub-Saharan African countries with a population of about 350 million people.
TABLE 13.2
Recent Outbreaks of Meningococcal Meningitis Worldwide
Time | Place | Number of Cases | Number of Deaths |
Until May 12, 1999 (10.7 million doses of vaccine were distributed to the affected states) | 19 states of Sudan | 22,000 | 1600 |
August–September 1999 | Angola (Yambala area) | 253 | 147 |
September–October 1999 | Rwanda | No reported numbers | |
October 1999 to January 2000 | Central African Republic | 86 | 14 |
December 1999 | Hungary | 30 | 4 |
January to March 2000 | Ethiopia | ||
Kobo District of Amhara Region | 81 | 3 | |
Alamata District of Tigray Region | 48 | 6 | |
2002 | Great Lakes region (Africa) | 2200 | 200 |
2002 | Burkina Faso (W-135 emerged) |
130,000 | 1500 |
2007 | “Meningitis belt” (Africa) | 54,676 | 4062 |
Haemophilus influenzae Meningitis
Prevention can be provided by several types of Hib vaccines available for children 2 months of age or older. Immunization is recommended for infants and children by the American Academy of Pediatrics, the National Institutes of Health, and other health agencies. Ideally, the first dose of the vaccine should be administered at the age of 2 months, followed by three or four booster vaccinations (see Chapter 20, The Immune System), depending on the brand of vaccine used.
Pneumococcal Meningitis
Pneumococci are also the cause of millions of cases of acute otitis media (middle ear infection) annually (Figure 13.4), and approximately 500,000 cases of pneumonia per year in the United States (see Chapter 11, Infections of the Respiratory System). Middle ear infections are one of the most common reasons for physician’s office visits in the United States, resulting in more than 20 million visits annually. In general, by the age of 12 months 60% of children have had at least one episode of acute otitis media. Complications of pneumococcal otitis media include mastoiditis and meningitis.
• High-risk persons age 2 years and over
• Everyone age 65 years and older
• Patients with sickle cell anemia
• Patients with chronic organ failure
• Residents of nursing homes and other long-term care facilities
• People who live in institutions with residents who have chronic health problems
• People with a compromised immune system such as patients with HIV, patients with cancer, or patients who have received an organ transplant
• Persons who receive long-term immunosuppressive drugs, including steroids
• Alaskan natives and certain Native American populations who are genetically predisposed
A serious problem with pneumococcal diseases including meningitis is the increasing emergence of antibiotic-resistant strains of S. pneumoniae (also see Chapter 11, Infections of the Respiratory System). Antibiotic-resistant strains are most likely to emerge in settings where antibiotics are commonly prescribed such as in hospitals, nursing homes, and day care centers. At present between 10% and 40% of all infections caused by S. pneumoniae are resistant to at least one antibiotic, but more and more multidrug-resistant strains are emerging in the United States. Therefore, vaccination of at-risk groups will play an even more important role in preventing pneumococcal disease in the near future.
HEALTHCARE APPLICATION
Bacterial Meningitis
Pathogen | Transmission/Symptoms | Treatment | Prevention |
Neisseria meningitidis |